Canada may see its first gene therapy by the end of this year. The treatment is for a very rare eye disorder, affecting just 100 to 200 Canadians, and comes at an estimated price of $1 million for both eyes. For larger patient populations, the 2020 TELUS Health Drug Pipeline report states that the two drug launches most likely to have an impact on private plans are in the areas of diabetes and depression. In both cases, the new therapies are for patients who struggle to manage their condition despite efforts to use existing therapies. While both are priced relatively much higher than first-line therapies, their potential to offset other healthcare costs, including absenteeism and lost productivity, is high. In the cancer category, researchers continue to find success in the development of targeted treatments based on genetic markers. The recent…
To read this article you must be logged in
We will use your email address to send you our newsletter. All communications will be from TELUS Health.
We will use your email address to send you our newsletter.
All communications will be from TELUS Health.
All fields are required